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INTRODUCTION
Vaccination is perhaps the most beneficial public health tool inhistory. The battle has been won for smallpox, diphtheria, polio,
measles, yellow fever and several other diseases (1), saving millions of
lives and changing the demographics of the world. However, the war is
not over and many challenges such as HIV, influenza, hepatitis C virus
(HCV), Mycobacterium tuberculosis, Malaria and others remain. Most
vaccines have been developed empirically and despite their success we
understand little about the ultimate mechanism of their protective
immunity. Although the majority of concepts of the new vaccine ap-
proaches stem from in vitro data, major insights still have to come from
in vivo analysis. The past decade has witnessed a significant progress in
elucidating mechanisms of vaccine-induced immune response (2, 3),
providing data necessary for rational development and design of 'smart'
vaccines.
The majority of current vaccines rely on protective immunity induc-
ed by infection with live, but attenuated pathogens. However, in most
of these approaches there is little or no external control over the process
of mounting the immune response. Depending on the protective prin-
ciple needed for controlling certain pathogens, different types of immu-
ne response may be desirable, including the production of protective
antibodies and various components of specific cellular immune res-
ponse. In addition, for successful protection against many pathogens, it
is essential that immune response mechanisms are operative at the site
of infection, e.g. mucosal tissue as the most frequent site of pathogen
entry. Novel approaches of vaccine development include delivery of the
gene of interest and expression of antigens within a host. These ap-
proaches provide much better possibilities to control the process of
inducing and maintaining a specific immune response, appropriate to
best counteract particular pathogen. The genes encoding the antigens
may be delivered to the host by introducing DNA, RNA, modified
bacteria or virus vectors. Also, synthetic peptides based vaccines and
peptide-loaded dendritic cells (DCs) show promising results as another
modality of vaccine approaches.
In this review we briefly discuss why traditional vaccine approaches
were not so effective against several present-day epidemic diseases.
Thereafter, we highlight some immunological principles that give
foundation to viral vector-driven vaccines. We put a special emphasis
on how the knowledge gained from cytomegalovirus can be used to
design more efficient vaccines and vaccine vectors against multiple
human pathogens.
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TRADITIONAL VERSUS MODERN
VACCINES
Traditional vaccines have shown an outstanding suc-
cess against several infectious diseases. Because they most
closely recapitulate a natural infection, live attenuated
vaccines are considered to be the best way to stimulate
both humoral and cellular arms of the immune system.
Vaccines against smallpox, mumps, rubella, yellow fever
and measles can elicit a long-lasting or lifelong protec-
tion with even a single dose (4, 5, 6). However, there are
many pathogens for which even the immunity acquired
after natural infection does not fully protect against re-
-infection and disease. Therefore, we need to devise vac-
cines which offer superior protective capacity compared
to those obtained by natural infection. For instance, hu-
man immunodeficiency virus (HIV) mutates rapidly
because its replication includes reverse transcription of
the single stranded RNA genome but lacks proofreading
mechanisms (7). The result is that each genome of the
viral progeny differs from the infecting viral genome in
about one nucleotide, which makes it antigenically very
heterogeneous (8, 9). Also, live attenuated HIV may
regain its virulence through mutations. In the case of
influenza virus, live attenuated or inactivated vaccines
confer some degree of protection by eliciting neutraliz-
ing antibodies to hemagglutinin (HA) and neuramini-
dase (NA), but frequent mutation of the genes encoding
for these major virion surface antigens leads to minor or
major antigenic differences between year-to-year strains,
resulting in the escape of the virus to antibody-based
neutralization (6, 10, 11). Similarly, the existence of mul-
tiple serotypes of the dengue virus makes it hard to
develop an effective vaccine by traditional methods (12).
Live attenuated vaccines have been proven inefficient or
of questionable safety in reinfection with respiratory syn-
cytial virus (RSV), malaria, persistent or latent infections,
such as hepatitis C virus (HCV), human papilloma virus
(HPV) and herpesviruses (13). Immunocompromised
patients and immunologically immature infants or
children are additional important factors to bear in mind
when developing live attenuated vaccines.
The second group of traditional vaccines includes
inactivated pathogens and subunit vaccines. The dis-
covery that inactivated pathogens may retain immuno-
genicity was the basis for the development of typhoid,
cholera, hepatitis A, whole-cell pertussis and whole virus
influenza vaccines. Subsequently, only the extracts of
pathogens were used to develop anthrax and pertussis
vaccine (14), or pathogen products were used to develop
toxoid vaccines against tetanus and diphtheria. Advance
of technology enabled the synthesis of polysaccharide
alone or protein conjugated polysaccharide vaccines against
meningococcus, pneumococcus and Haemophilus influ-
enzae type b and recombinant protein based subunit
vaccine against hepatitis B virus (14) and HPV (15).
This group of vaccines may be more safe and stable, as
compared to live attenuated vaccines, but their stimu-
lation of the immune system is weaker, raising the need
for several booster doses to maintain the appropriate
level of immune protection over the time. Further, these
vaccines are oriented more towards the production of
antibodies, leaving the cellular immune response in-
adequate (16) and often requiring adjuvants to modulate
the quality of immune response. Pulsing synthetic pep-
tides into DCs in vitro resulted in production of several
experimental dendritic cell-based vaccines (17), since
DCs are major antigen-presenting cells and potent ini-
tiators of primary immune responses when pulsed with
antigens (18). Several more vaccine approaches, includ-
ing peptide-based vaccines for cancer, are in different
stages of research.
IMMUNE RESPONSE TO VACCINES
The fact that the most currently used vaccines rely on
the induction of neutralizing antibodies has, for many
years, put aside the development of vaccines based on
protective cellular immune response. Indeed, antibodies
are extremely powerful in the protection against many
pathogens or their products; however, vaccines, or even
natural infection with some viral pathogens, often fail to
induce a sufficiently protective neutralizing antibody
response. This is particularly notable for HIV, since most
vaccines based on the induction of antiviral antibodies
have failed so far (19, 20, 21, 22). Therefore, the need for
developing vaccines based on the induction of protective
cellular immunity, which rely on T-cells, particularly
cytotoxic CD8+ T-cells, became imminent (23, 24). Mo-
reover, research on vaccines that induce T-cell immunity
has dominated a great deal of recent development efforts.
Although T-cells are well known for their capacity to
contain viral infection, it turns out that the development
of T-cell based vaccine is not so straightforward. The
reasons for this may be several-fold. Many pathogens,
particularly viruses, possess powerful mechanisms to
interfere with immune response mechanisms, including
T-cells. Furthermore, unlike antibodies, memory T-cells
need some time after encountering their cognate antigen
to express effector function and it may already be too late
for some pathogens. This means that we need vaccines
which are able to limit viral infection at a very early stage.
It is likely that neither the approach based solely on the
induction of neutralizing antibody, nor the one based on
CD8+ T-cell response will be successful – what we need
are vaccine platforms that could induce both. Moreover,
modern vaccine and vaccine vectors aimed at protecting
against immunosubversive viruses, such as HIV, need to
induce a more powerful cellular immune response of
different quality than the one induced by natural in-
fection (25).
CD8
+
T-CELL RESPONSE TO VACCINES
It is current belief that a better understanding of the
biology of memory T-cell subsets and their homeostasis is
crucial for designing efficient vaccines based on cellular
immunity. Priming of antigen-specific T-cells takes place
in secondary lymphoid tissues triggered by dendritic cells,
which present foreign peptides in context of either MHC
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class I, or class II antigens (26). This leads to the expansion
of antigen-specific T-cells and their differentiation and
maturation to antigen-specific effector T-cells, which dis-
seminate to non-lymphoid tissues and control infection.
Upon clearance of infection, the frequency of these cells
contracts, leaving memory T-cells which enable more
efficient recall response to cognate antigen and protection
against reinfection (27). Keeping in mind that CD8+
T-cells control viral infection by recognition of foreign
peptides, presented in context of MHC class I molecules
on infected cells, and that CD8+ cells can see several
peptides of the same pathogen, or even of the same pro-
tein, the chances that the virus will escape CD8+ recogni-
tion are smaller than the viral escape from neutralizing
antibodies. In addition, unlike antibodies which are
neutralizing only when they recognize surface viral
proteins, CD8+ T-cells can recognize foreign peptides
derived from any viral protein, including non-structural
proteins (28, 29). The only way for the viruses to avoid
such a powerful recognition mechanism is through
interference with antigen processing and presentation,
which is indeed the nature of many immunosubversive
viruses (30). The above mentioned characteristic of CD8+
T-cells as effector cells can be exploited for designing
preventive CD8+ T-cell vaccines. In addition, we now
know that CD8+ T-cell response can be modulated by
means of innate immune response (30). Therefore, when
designing vaccines based on CD8+ cell response, one has
to bear in mind not only the viral immunoevasion mecha-
nisms, but also the capacity of innate immune system to
modulate CD8+ T-cell response.
Memory CD8+ T-cells are roughly divided into two
major subsets, based on the differential expression of
homing receptors: central memory CD8+ T-cells (TCM),
which express CD62L and CCR7, and effector memory
CD8+ T-cells (TEM), lacking those two markers (31).
While TCM travel through secondary lymphoid tissues
and blood, representing long-lived memory cells with
high proliferative capacity upon restimulation, TEM
re-circulate through the nonlymphoid tissues where they
may be directly involved in virus control (31). We now
know that the cellular distribution and frequency of
these memory cell subsets may be essential for the ef-
ficacy of immune response after challenge infection, but
the mechanisms which are involved in the differentia-
tion and maintenance of these subsets are still the subject
of intensive research in the field (25, 32, 33). Keeping in
mind that CD8+ TEM have a potentially better chance to
contain infection at its initial site (e.g. muscosa), one can
speculate that successful vaccines for such pathogens
need to favour the induction of this type of memory
T-cells (see below).
VACCINE VECTORS
Vectors are delivery systems that usually derive from
pathogens and deliver foreign genes to express the
antigens in situ (6). Plasmid DNA, RNA and modified
viruses or bacteria can be used to deliver the antigen
coding information to the organism. For instance, DNA,
RNA and oligonucleotides are easily delivered into the
cells in vitro by means of transfection for recombinant
protein expression or regulation of gene expression.
There have been several methods explored to increase
the potency of these vaccines, such as co-transfection
with non-coding bacterial plasmid containing CpG
motifs, thus stimulating Toll-like receptor 9 (TLR9) and
attracting the cells of innate immunity (34, 35), changing
the promoters to increase the gene expression (36), or
co-expressing of cytokines and other immunomodula-
tory molecules. The exciting research in this field has
already resulted in several vaccines approved for use in
animals, and many open clinical trials in phases I to III,
exploring this approach in the prevention or therapy of,
not only infectious, but also cardiovascular and neuro-
logical diseases and cancer [reviewed in (37)].
Bacterial vectors can also be used to deliver plasmids
or protein antigens expressed within them in vivo. Both
approaches have been evaluated in different studies and
have shown controversial results (38). Amongst the most
used bacterial vectors in research are Salmonella, Myco-
bacteria and Listeria. Invasive bacteria, such as Listeria
monocytogenes and Shigella spp., are able to replicate within
the cytoplasm of mammalian cells. Upon lysis, the bac-
terial content can be released directly into the cytosol of
infected cells, providing access to the MHC class I pre-
sentation pathway (39). Attenuated and modified for
vaccine purposes, bacteria may enter the organism in
their natural manner, stimulating diverse immune res-
ponses (systemic and mucosal), and, if located intra-
cellularly, deliver the gene or protein to APCs.
VIRAL VECTORS
The characteristic of viral vectors, such as their cell
tropism, capacity for carrying heterologous genetic ma-
terial, quantity of expression of heterologous genes, abi-
lity to induce diverse immune response and persistence
in host, are some of the factors influencing the selection
of a particular viral vector to its specific application.
Viruses have evolved highly effective mechanisms for
entering the cells and using their machinery for the
expression of viral proteins (40, 41). This property has
made them very attractive as transporters of the genes of
interest into the cell. Advances in molecular biology have
made possible the modification of the viral genome,
rendering viruses highly attenuated or replication-de-
ficient (i.e. safe) and, at the same time, capable of in-
fecting the cell and delivering the genetic material. Viral
vectors offer many advantages compared to traditional
vaccines, including robust antibody response, but, more
importantly, they activate both CD8+ and CD4+ T-cell
response that is essential for control of intracellular
pathogens and cancer (42). Additionally, by using viral
vectors, immune response can be focused on a particular
protein, or even epitope, conserved between different
strains of pathogens, making them useful for creating
universal heterosubtypic vaccines (e.g. for Influenza) (43,
44). However, viral vectors may have several weaknesses.
First of all, attenuated viruses may gain virulence in vivo,
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making the vaccine vector unsafe. Secondly, these vectors
may also recombine with endogenous viruses and gain
their virulence. Under the selective pressure imposed by
the immune system, viruses may mutate or delete the
inserted foreign genes and lose antigenicity. Pre-existing
immunity against viruses that commonly infect the hu-
man population can be a major problem. This is par-
ticularly the case for adenovirus vectors, and also for
herpesvirus vectors. Many efforts to overcome the pro-
blem of pre-existing immunity are underway, including
the development of different serotypes of viral vectors as
well as the better design of prime-boost approaches.
The list of recombinant virus vectors that have been
tested for vaccines is extensive and includes adenoviru-
ses, adeno-associated viruses, vesicular stomatitis virus,
polio virus, etc. One should not forget pox viruses, which
have the longest use in human history, since the vaccina-
tion with vaccinia virus resulted in the eradication of
smallpox. In addition to adenovirus vectors, several
members of the pox virus family are currently under
evaluation as vaccine vectors (41).
Despite many disappointing outcomes in attempts to
generate an efficient HIV vaccine (45, 46), a recent trial
in Thailand, using prime-boost regimen consisting of
Canary pox vector (Alvac-HIV, Sanofi Pasteur), followed
by GP120 in Alum (AIDSVAX B/E Global Solutions for
Infectious Diseases) clearly demonstrated the positive
effect with regard to preventing HIV infection in the
population at risk (47). Curiously, and in contrast to
what was expected, the data failed to provide any evi-
dence that protection was mediated through CD8+ res-
ponse, although the pox virus as a vector is clearly a good
inducer of these cells.
HERPESVIRUSES – VACCINES AND
VECTORS
Herpesviruses are a large family of DNA viruses,
among which eight can cause diseases in humans, parti-
cularly in children and in immunocompromised indi-
viduals. Herpesviruses can be subdivided into the a-, b-
or g- subfamilies based on their biological and sequence
characteristics, but they share common features such as
the establishment of persistence and latency in specific
cell types, and the ability to cause lytic infection in per-
missive cells (48).
Persistence in host and intermittent reactivation are
key features of the herpesvirus infections. These features,
however, in the context of viral vectors, may translate to
periodic antigenic restimulation, which is highly desired
for the induction and maintenance of effector T-cell
response. The development of vaccines against herpes-
viruses has major public health significance. A range of
vaccine platforms, has been used thanks to the major
advances in molecular biology and genetic engineering
(49). Varicella-zoster virus (VZV), and herpes- simplex
virus (HSV) have also been extensively researched as
vectors for vaccines against HIV (50, 51, 52, 53, 54), and
several other pathogens (55, 56, 57).
In spite of the outstanding properties of herpesviruses
to induce potent immune response, including the res-
ponse to vectored antigens, one should keep in mind that
the use of live persistent viruses bears the risk of recombi-
nation of attenuated herpesvirus vaccine or vaccine vec-
tors and the restoration of virulence, as recently demon-
strated for laryngotracheitis herpesvirus (58). Yet, a large
proportion of herpesvirus genomes are occupied by
non-essential genes encoding viral immunoevasins and
other genes involved in interaction with host cells.
Deletion of these genes usually does not compromise
virus growth in vitro, but, alternatively, results in strong
attenuation in vivo (59, 60). Thus, it is unlikely that such
deletion mutant viruses could easily recombine to regain
the virulence. In addition, as will be discussed below,
further manipulation with herpesviral genome, such as
insertion of genes encoding ligands for various immune
receptors, should make such a vector extremely sensitive
to immune control (61). We assume that, in spite of the
obvious resistance of regulatory agencies to approve live
recombinant persistent viruses as vaccine vectors, ac-
cumulated data point out that many of them may reach
the highest level of safety standards. The use of recom-
binant viruses, such as a CMV vaccine and CMV-based
vaccine vector, will be discussed further in the text.
CMV VACCINES
The Committee for Vaccine Development at the Ins-
titute of Medicine (The National Academies, Washing-
ton DC) ranked human cytomegalovirus (HCMV) vac-
cine, aimed to prevent congenital HCMV infection, among
the candidate vaccines of the highest priority (62). In
order to design any successful vaccine, vaccines against
persistent viruses in particular, it is essential to under-
stand its biology and the immune response mechanisms
involved in its control. Human cytomegalovirus (HCMV)
is ubiquitous in humans, with seroprevalence rates from
50 to 90%. After primary infection, the immune response
effectively terminates virus replication. However, the clea-
rance of the viral genome is not achieved, and HCMV
establishes a lifelong latency with periodic reactivation
and virus shedding (63). While HCMV infection is rea-
dily controlled in an immunocompetent host, the virus
displays its severe pathogenic potential when immune
control is impaired. Although there is sound basis to
believe that vaccination may ameliorate HCMV infec-
tion or disease in some high-risk populations, any vac-
cine approach must take into account different clinical
situations.
The components of innate immunity, particularly the
natural killer (NK) cells, are considered important for
early virus control, but components of specific immune
response are needed for termination of productive infection
and establishment of latency (64). Among them, CD8+
T-cells play a major role in the control of primary CMV
infection, whereas antiviral antibodies are responsible
for virus neutralization after the reactivation from laten-
cy (65, 66, 67, 68). Notably, CD8+ T-cells specific for
mouse CMV (MCMV) have been shown to slowly
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accumulate after the primary infection has been resolved
(69, 70). The protective capacity was associated with the
emergence of epitope-specific CD8+ TEM cells, which
provide long-term protection and apparently undergo
continuous activation and proliferation. The expansion
of the memory pool of CD8+ (and CD4+) T-cells spe-
cific to HCMV (71) was also described. Altogether, any
attempt to prevent or ameliorate the primary CMV in-
fection should bear in mind the key role of both innate
and acquired cellular immune control whereas the qua-
lity of antiviral antibody response determines the ability
of the host to limit virus spread after reactivation and
re-infection. Another hallmark of all CMVs is the pre-
sence of a large range of so-called 'immune evasion'
genes, targeting the host immune response, whose
function may influence the success of the vaccine itself.
Numerous studies using viral mutants, carrying targeted
deletions in regions of CMV containing immunoevasive
genes, have demonstrated their importance as virulence
factors in vivo (72).
A number of CMV vaccine strategies have been de-
veloped, including: protein vaccines, DNA vaccine, pep-
tide vaccines, dense bodies’ vaccines, virally vectored
vaccines and live attenuated vaccines (73, 74, 75). Unlike
subunit vaccines, which induce immunity to selected
viral antigens, live virus vaccines elicit an immune res-
ponse which mimics natural immunity and provides
broader protection. The use of live virus vaccines, how-
ever, carries the risk of reactivation of the vaccine strain
in immunocompromised patients, unless such vaccine
virus is susceptible to residual immune control preserved
after immunosuppression. For instance, if some compo-
nents of innate immunity are preserved after immuno-
suppression (e.g., NK cells) and the vaccine virus is
sensitive to them, one would expect that any recurrence
of the vaccine virus would be controlled. One such
pre-clinical approach to generate immunogenic, yet safe,
live vaccine is the deletion of viral genes that subvert host
immune response (59, 76). Another approach would be
the insertion of ligands, for activating receptors on
immune cells, into the CMV genome (Figure 1). We
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Figure 1.Despite profoundly attenuated replication in vivo and reduced antigenic load as compared to theWTMCMV, recombinant virus expressing
NKG2D ligand RAE-1g instead of its viral inhibitor m152 efficiently primes and maintains virus-specific CD8+ T cell response. Naive CD8+ T
cells require engagement of TCR by MHC-I molecules on antigen presenting cells (APCs) in order to be activated. (A) MCMV has evolved several
mechanisms for evading the immune system and thus escaping the virus clearance. Wild-type MCMV (WT MCMV) downregulates MHC class I and
co-stimulatory molecules from the surface of infected APCs and reduces their capacity for direct T cell priming. Consequently, the cross-priming
becomes the dominant mechanism in generation of specific CD8+ cells following WT MCMV infection. However, infection with MCMV mutants
lacking MHC class I evasion genes (e.g., m152) and other immunoevasins or mutants possessing insertion of genes encoding cellular ligands for
activating receptors (e.g., RAE-1g) may improve not only virus control but also T cell/APCs interaction and CD8+ T cell priming. Accordingly,
despite profoundly attenuated replication in vivo and reduced antigenic load as compared to the WT MCMV, RAE-1gMCMV efficiently primes and
maintains virus-specific CD8+ T cell response (61, 85). (B) Similar to WT MCMV infection, T cell induced by RAE-1gMCMV is of dominantly of
TEM phenotype.
have recently combined these approaches, designing an
experimental CMV vaccine encoding ligand for NKG2D
receptor, and demonstrated excellent characteristics of
such virus (61). In fact, the idea was to create an ex-
perimental CMV vaccine, extremely sensitive to control
by NK cells, but at the same time, able to prime and
maintain robust virus-specific response. Such an idea
has been somewhat against the current dogma, since it is
believed that the intensity of virus replication and anti-
genic load positively influences ongoing immune res-
ponse (64, 77). To achieve both, strong attenuation and
potent antiviral response, we inserted Rae-1, the cellular
ligand for the NKG2D receptor, in place of its viral
inhibitor. Thus, the obtained recombinant virus was able
to activate NK cells via NKG2D and circumvent all
other immunoevasion mechanisms. At the same time,
the priming of the antiviral T-cell response was equal to,
or even higher, than in mice infected with the WT
MCMV strain.
The powerful immune response was probably a con-
sequence of NKG2D co-stimulation, since this receptor
plays a co-stimulatory function on CD8+ cells. More-
over, we have shown that the vaccination of female mice
before pregnancy results in the induction of an antiviral
antibody response which, after transplacental transfer,
can protect newborn mice from lethal MCMV infection.
The two other features of such recombinant vaccine are
worth mentioning. Firstly, it is attenuated even in mice
lacking a receptor for type I interferons (IFNAR k.o.
mice), or mice immunosuppresed by sublethal gamma
irradiation, which are otherwise extremely susceptible to
this virus. Secondly, since such a virus is under stringent
selective pressure by NK cells in vivo, one would expect
the viral escape from NK cell control by mutation or
deletion of Rae-1 transgene. Surprisingly, unlike in the
case of the m157 gene, which is subject to numerous
mutations and deletions when the virus is exposed to NK
cells expressing Ly49H receptor (78), the gene encoding
Rae-1, expressed in MCMV, remained completely intact,
even when reactivated several months after infection.
Altogether, the work by Slavuljica and colleagues nicely
demonstrates that one can design a CMV vaccine or
CMV-based vaccine vector which does not cause disease,
even in immunologically immature and immunode-
ficient hosts, but is at the same time able to induce strong
antiviral immunity. Based on the results presented above,
one can predict that a similar virus could serve as an
excellent vaccine vector (79).
CMV-BASED VACCINE VECTORS
As mentioned above, CMVs are excellent inducers of
virus-specific CD8+ T-cell response, in spite of the nu-
merous immunoevasion mechanisms aimed to compro-
mise antigen presentation in context of MHC class I
molecules (80). Indeed, a recent study demonstrates the
ability of MCMV-based vaccine vector expressing CD8
epitope of Ebola virus nucleoprotein to protect against
challenge infection with this virus (81). The ability of
attenuated recombinant CMVs to induce and maintain
robust immune response was most likely the reason for
efforts in preclinical studies aimed at developing an HIV
vaccine, based on CMV as a vector. Hansen and co-
-workers used rhesus macaques injected with rhesus
CMV (RhCMV) expressing simian immunodeficiency
virus (SIV) genes, and tested its capacity to induce SIV-
-specific CD8+ T-cells (Figure 2). Indeed, they were the
first to demonstrate that majority of animals vaccinated
with the RhCMV/SIV recombinant virus, expressing
multiple SIV proteins, could resist progressive infection
following repeated SIV administration via an intrarectal
route (82). Next, they showed that this CMV-based vac-
cination preferentially induces CD8+ T-cells of effector
memory phenotype, which should therefore be able to
restrict SIV replication on the site of infection. Moreover,
they compared the vaccination with RhCMV/SIV re-
combinant virus to the conventional recombinant ade-
novirus vaccine that predominantly induces central memory
T-cells (83). The obtained results were very encouraging
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Figure 2. RhCMV vectors expressing SIV genes induce a strong and
protective effector- memory T cell response in rhesus macaques. Three
different vaccination protocols which included RhCMV-SIV, Ad5-SIV
vectors and plasmids with SIV genes, were recently compared by
Hansen et al. (83). The first group of animals received RhCMV-SIV
vector alone; the second group was primed with RhCMV-SIV vector
and boosted with Ad5-SIV vector, while the third group was primed
with plasmids containing SIV genes and boosted with Ad5-SIV vector.
The effects of various vaccine approaches with respect to T cell response
and virus control after challenge infection with highly pathogenic SIV
are schematically displayed.
with regard to the potential of generating HIV vaccine
using similar approach and HCMV as a vector. Namely,
the repeated rectal challenge infections of primed ani-
mals with SIV showed a remarkable protection in majo-
rity of animals challenged with transient SIV viremia
followed by decrease in virus load. Additionally, periodic
SIV reactivation was also less frequent over the time,
which is in stark contrast to the course of persistent SIV
infection and high level of virus replication in unvac-
cinated macaques. The efficacy of this vaccine approach
as compared to others, which are also able to induce
CD8+ T-cells, is likely to be related to the ability of
RhCMV/SIV vector to induce effector memory CD8+
T-cells which became resident in mucosal tissue. This
close proximity of memory CD8+ cells to the site of SIV
infection seems to be essential for early containment of
SIV infection, which was not the case with vaccines
unable to induce effector memory CD8+ T-cells in mu-
cosal tissue. Altogether, the above mentioned studies
demonstrated that CMV-based vaccine vector can be
used to induce the protective T-cell response which is
able to contain SIV infection. Therefore, these studies
indeed shed the new light on the development of
preventive HIV vaccine by using persistent herpes viral
vectors (84).
CONCLUDING REMARKS
Recent developments in the use of viruses as vaccine
vectors have been enhanced by expanding knowledge of
immunology and viral biology. It is current dogma that
the optimal vaccine platform should induce both cellular
and humoral immune response. It is well established
that live attenuated virus vaccines and vectors still re-
present the best inducers not only of cellular immunity,
but also of antibody response. As there are a large num-
ber of pathogens for which even the immunity acquired
after natural infection does not fully protect against re-
-infection and disease, we need to devise vaccines which
offer superior protective capacity compared to those ob-
tained by natural infection. At present, a wide range of
viruses, replication competent and attenuated, are under
development as vaccine vectors for human use. Several
preclinical studies on animal models, including non-
-human primates, indicate the capacity of these per-
sistent herpesvirus vectors to elicit and maintain potent
memory T and B cell response. Several sets of data
indicate that, by deleting various herpesviral immuno-
evasion genes and/or by inserting cellular ligands for
activating immune receptors, one can create vectors that
can induce robust protective immunity in spite of dra-
matic attenuation. We believe that similar platforms can
be used in the development of vaccination strategies
against multiple human pathogens.
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